Cyclophosphamide (CPA)

DRUG3 trials

Sponsors

Merck KGaA, Darmstadt, Germany, EMD Serono

Conditions

Carcinoma, Non-Small-Cell LungNon-small Cell Lung Cancer (NSCLC) Stage IIIRectal Cancer

Phase 1

Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer

WithdrawnNCT01731587

Merck KGaA, Darmstadt, GermanyNon-small Cell Lung Cancer (NSCLC) Stage III

Start: 2001-01-31Updated: 2017-02-28

Phase 2

Tecemotide (L-BLP25) in Rectal Cancer

CompletedNCT01507103

Merck KGaA, Darmstadt, GermanyRectal Cancer

Start: 2012-02-29End: 2014-06-30Updated: 2017-01-13

Phase 3

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

TerminatedNCT02049151

EMD SeronoCarcinoma, Non-Small-Cell Lung

Start: 2014-03-31End: 2015-07-31Updated: 2017-08-23

Related Papers

Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.

2025-05-221 citations

START2: Tecemotide in unresectable stage III NSCLC after first-line concurrent chemoradiotherapy.

Journal of Clinical Oncology2014-05-205 citations